PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
Rhea-AI Summary
10x Genomics (Nasdaq: TXG) announced a partnership with PharosAI, a UK consortium of four institutions, to build one of the world's largest multimodal cancer datasets using the Xenium spatial platform.
Backed by £18.9 million from the UK Research Ventures Catalyst and partners, the program will convert thousands of archived NHS cancer samples into AI-ready genomic, transcriptomic, imaging and spatial biology data, run through 2027, and democratize secure access for researchers worldwide.
Positive
- £18.9 million UK government backing for PharosAI
- Plan to convert thousands of archived NHS tissue samples
- Creation of one of the world's largest multimodal cancer datasets
- Program timeline running through 2027 to scale data generation
Negative
- No financial or commercial terms between 10x Genomics and PharosAI disclosed
News Market Reaction
On the day this news was published, TXG declined 1.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TXG fell 3.36% with peers also weak: CERT -6.85%, OMCL -5.52%, SDGR -5.24%, GDRX -4.85%, PHR -2.67%, suggesting broader pressure despite AI-positive news.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | AI oncology initiative | Positive | -3.2% | Multi-phase AI immuno-oncology program using >20,000 samples with 10x tech. |
| Oct 20 | AI tool integration | Positive | +11.1% | Integrating 10x analysis workflows into Claude for Life Sciences via MCP. |
| Jul 17 | AI drug discovery study | Positive | +0.7% | TISHUMAP collaboration using Xenium and AI on up to 2,500 cancer samples. |
| Feb 06 | Billion Cells AI project | Positive | -0.3% | CZI Billion Cells Project with 10x tech to build vast AI training dataset. |
AI collaborations often see mixed reactions: two prior AI releases drew gains, two saw modest declines.
Recent AI-related news for 10x Genomics shows recurring partnerships that expand single cell and spatial data for machine learning. On Jan 12, 2026, an AI-driven immuno-oncology initiative using 20,000+ samples saw a -3.23% move. Earlier, collaborations with Anthropic (Oct 20, 2025), A*STAR’s TISHUMAP study (Jul 17, 2025), and CZI’s Billion Cells Project (Feb 6, 2025) produced small gains or mild declines. Today’s PharosAI partnership continues this AI-and-spatial theme.
Historical Comparison
In the past year, TXG released 4 AI‑tagged collaborations with an average move of 2.04%. Today’s -3.36% decline on another AI dataset partnership sits at the weaker end of that range.
AI-tagged news shows a progression from foundational Billion Cells and TISHUMAP datasets to broader clinical and immuno-oncology programs, now extending into large NHS cancer archives via PharosAI.
Market Pulse Summary
This announcement deepens 10x Genomics’ role at the intersection of AI and spatial biology, pairing the Xenium platform with PharosAI’s large multimodal cancer datasets funded by £18.9 million. It follows prior AI collaborations focused on expansive single cell datasets. Key considerations include how quickly these research programs translate into recurring consumables demand, platform standardization in major centers, and evidence that AI-ready datasets drive new diagnostics or partnerships through at least 2027.
Key Terms
spatial biology medical
transcriptomic medical
AI-generated analysis. Not financial advice.
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine
PharosAI brings together King's College London, Queen Mary University of
"AI has the potential to transform cancer care, but its progress has been held back by fragmented and inaccessible data," said Professor Anita Grigoriadis, CEO of PharosAI and Professor of Molecular and Digital Pathology at King's College London. "PharosAI changes that - creating rich, multimodal datasets and pairing them with cutting-edge AI models and analytical tools, powered by 10x Genomics' advanced spatial technologies to enable earlier diagnoses, more targeted therapies and better outcomes for patients. By uniting universities, NHS Trusts, charities and industry, we are building an ecosystem for breakthrough discoveries."
The initiative will launch with a major focus on breast cancer, before expanding to lung and pancreatic cancer, with plans to include thousands of clinical tissue samples. By combining genomic, transcriptomic, imaging and spatial biology data, and linking them with a suite of custom AI models and analytical capabilities, PharosAI will produce AI-ready datasets capable of revealing patterns that have remained hidden until now. With Xenium providing spatial insights and advanced AI models uncovering new biology, researchers will be able to ask bigger questions and move faster toward the discovery of new diagnostics and therapies.
To support a study of this scale, PharosAI required a spatial platform capable of delivering reproducible results across thousands of archival tissues. Xenium's high-throughput workflow, combined with the ability to generate custom-designed gene panels in collaboration with 10x teams, enabled the consortium to configure assays aligned with the molecular features most relevant to specific cancers.
"Turning biological insight into impact requires scaled generation of consistent, high-quality data," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "With Xenium, PharosAI can convert decades of archived NHS cancer samples into robust, high-quality, spatially resolved datasets. This foundation is what makes it possible to move earlier, more precisely and with greater confidence toward the next generation of breakthroughs in cancer research."
Importantly, PharosAI will democratize access to these datasets, ensuring they are securely available to a broad community of researchers and innovators. This ambitious program, running through 2027, positions the
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
About King's College London
King's College London is amongst the top 40 universities in the world and top 10 in
King's has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and 8,500 staff.
For nearly 200 years, King's students and staff have used their knowledge and insight to make a positive impact on people, society and the planet. Focused on delivering positive change at home in
World-changing ideas. Life-changing impact: kcl.ac.uk/news
About Guy's and
Guy's and
As one of the biggest NHS trusts in the
About Barts Health NHS Trust
With a turnover of
About Barts Life Sciences
Barts Life Sciences is a partnership between Barts Health NHS Trust and Queen Mary University of
About Queen Mary University of
At Queen Mary University of
Our reformer heritage informs our conviction that great ideas can and should come from anywhere. It's an approach that has brought results across the globe, from the communities of
We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharosai-and-10x-genomics-partner-to-transform-cancer-research-with-ai-and-spatial-biology-302678310.html
SOURCE 10x Genomics, Inc.
FAQ
What is the 10x Genomics (TXG) and PharosAI partnership announced February 4, 2026?
How much funding supports the PharosAI initiative using 10x Genomics Xenium (TXG)?
Which institutions are involved in PharosAI that will use 10x Genomics (TXG) technology?
What cancers and sample scale will the 10x Genomics (TXG)-backed PharosAI study focus on?
How will the datasets produced with 10x Genomics (TXG) Xenium be shared with researchers?
